Johnson & Johnson's Covid-19 Vaccine Safe, Well-tolerated

Johnson & Johnson announced that its Covid-19 vaccine candidate, JNJ-78436735, being developed by its unit Janssen Pharmaceutical Companies and currently undergoing in a Phase 3 trial, has been found to be safe and well tolerated. The interim Phase 1/2a data was published on Wednesday in the New England Journal of Medicine. A preview of part of these interim data was posted on medRxiv in September